Novel biomarkers for predicting intrauterine growth restriction: A systematic review and meta-analysis

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 120, Issue 6, 2013, Pages 681-694

  Conde Agudelo, A ^a,d   Papageorghiou, A T ^b,c   Kennedy, S H ^b,c   Villar, J ^b,c  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Biomarker; intrauterine growth restriction; meta analysis; prediction; systematic review

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; A DISINTEGRIN AND METALLOPROTEASE 12; ACTIVIN A; ALBUMIN; ANGIOPOIETIN 2; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; ENDOGLIN; EOTAXIN; FIBRONECTIN; FMS LIKE TYROSINE KINASE 1; FOLIC ACID; GAMMA INTERFERON; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; ISOPROSTANE DERIVATIVE; LACTATE DEHYDROGENASE; LEPTIN; N(G),N(G) DIMETHYLARGININE; PENTRAXIN 3; PLACENTAL GROWTH FACTOR; RANTES; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VITAMIN D;

ARTICLE; BIRTH WEIGHT; CASE CONTROL STUDY; CLINICAL FEATURE; FEMALE; HUMAN; INTRAUTERINE GROWTH RETARDATION; MEASUREMENT ACCURACY; META ANALYSIS (TOPIC); METABOLOMICS; OBSERVATIONAL STUDY; OXIDATIVE STRESS; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW (TOPIC); THYROID FUNCTION TEST;

BIOLOGICAL MARKERS; FEMALE; FETAL GROWTH RETARDATION; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; SENSITIVITY AND SPECIFICITY;

EID: 84876155750     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.12172     Document Type: Article

References (88)

1. ACOG Practice Bulletin. Intrauterine growth restriction. Number 12, January 2000. Clinical management guidelines for obstetrician-gynecologists. Int J Gynaecol Obstet 2001; 72: 85-96.
2. de Onis M, Blössner M, Villar J,. Levels and patterns of intrauterine growth retardation in developing countries. Eur J Clin Nutr 1998; 52 (Suppl 1): S5-15.
3. Villar J, Carroli G, Wojdyla D, Abalos E, Giordano D, Ba'aqeel H, et al. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol 2006; 194: 921-31.
4. Kady SM, Gardosi J,. Perinatal mortality and fetal growth restriction. Best Pract Res Clin Obstet Gynaecol 2004; 18: 397-410.
5. Pallotto EK, Kilbride HW,. Perinatal outcome and later implications of intrauterine growth restriction. Clin Obstet Gynecol 2006; 49: 257-69.
6. Leitner Y, Fattal-Valevski A, Geva R, Eshel R, Toledano-Alhadef H, Rotstein M, et al. Neurodevelopmental outcome of children with intrauterine growth retardation: a longitudinal, 10-year prospective study. J Child Neurol 2007; 22: 580-7.
7. Barker DJ,. Adult consequences of fetal growth restriction. Clin Obstet Gynecol 2006; 49: 270-83.
8. Varvarigou AA,. Intrauterine growth restriction as a potential risk factor for disease onset in adulthood. J Pediatr Endocrinol Metab 2010; 23: 215-24.
9. Tjoa ML, Oudejans CB, van Vugt JM, Blankenstein MA, van Wijk IJ,. Markers for presymptomatic prediction of preeclampsia and intrauterine growth restriction. Hypertens Pregnancy 2004; 23: 171-89.
10. Breeze AC, Lees CC,. Prediction and perinatal outcomes of fetal growth restriction. Semin Fetal Neonatal Med 2007; 12: 383-97.
11. Tuuli MG, Odibo AO,. First- and second-trimester screening for preeclampsia and intrauterine growth restriction. Clin Lab Med 2010; 30: 727-46.
12. Morris RK, Cnossen JS, Langejans M, Robson SC, Kleijnen J, Ter Riet G, et al. Serum screening with Down's syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. BMC Pregnancy Childbirth 2008; 8: 33.
13. Hui D, Okun N, Murphy K, Kingdom J, Uleryk E, Shah PS,. Combinations of maternal serum markers to predict preeclampsia, small for gestational age, and stillbirth: a systematic review. J Obstet Gynaecol Can 2012; 34: 142-53.
14. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003; 326: 41-4.
15. Spencer K, Cowans NJ, Avgidou K, Molina F, Nicolaides KH,. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses. Ultrasound Obstet Gynecol 2008; 31: 15-9.
16. Pihl K, Sørensen TL, Nørgaard-Pedersen B, Larsen SO, Nguyen TH, Krebs L, et al. First-trimester combined screening for Down syndrome: prediction of low birth weight, small for gestational age and pre-term delivery in a cohort of non-selected women. Prenat Diagn 2008; 28: 247-53.
17. Montanari L, Alfei A, Albonico G, Moratti R, Arossa A, Beneventi F, et al. The impact of first-trimester serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A on the diagnosis of fetal growth restriction and small for gestational age infant. Fetal Diagn Ther 2009; 25: 130-5.
18. Goetzinger KR, Singla A, Gerkowicz S, Dicke JM, Gray DL, Odibo AO,. The efficiency of first-trimester serum analytes and maternal characteristics in predicting fetal growth disorders. Am J Obstet Gynecol 2009; 201: 412.e1-6.
19. Marttala J, Peuhkurinen S, Laitinen P, Gissler M, Nieminen P, Ryynanen M,. Low maternal PAPP-A is associated with small-for-gestational age newborns and stillbirths. Acta Obstet Gynecol Scand 2010; 89: 1226-8.
20. Kirkegaard I, Henriksen TB, Uldbjerg N,. Early fetal growth, PAPP-A and free β-hCG in relation to risk of delivering a small-for-gestational age infant. Ultrasound Obstet Gynecol 2011; 37: 341-7.
21. Zhang J, Merialdi M, Platt LD, Kramer MS,. Defining normal and abnormal fetal growth: promises and challenges. Am J Obstet Gynecol 2010; 202: 522-8.
22. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J,. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.
23. Whiting P, Harbord R, Kleijnen J,. No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Med Res Methodol 2005; 5: 19.
24. Sankey S, Weisfiels L, Fine M, Kapoor W,. An assessment of the use of the continuity correction for sparse data in meta-analysis. Commun Stat Simul Comput 1996; 25: 1031-56.
25. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH,. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005; 58: 982-90.
26. Walter SD,. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 2002; 21: 1237-56.
27. Zwinderman AH, Bossuyt PM,. We should not pool diagnostic likelihood ratios in systematic reviews. Stat Med 2008; 27: 687-97.
28. Jaeschke R, Guyatt GH, Sackett DL,. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994; 271: 703-7.
29. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
30. Lijmer JG, Bossuyt PM, Heisterkamp SH,. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat Med 2002; 21: 1525-37.
31. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analyses detected by a simple graphical test. BMJ 1997; 315: 629-34.
32. Tjoa ML, van Vugt JM, Mulders MA, Schutgens RB, Oudejans CB, van Wijk IJ,. Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol 2001; 98: 600-7.
33. Bersinger NA, Ødegård RA,. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand 2004; 83: 37-45.
34. Krauss T, Pauer HU, Augustin HG,. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004; 23: 101-11.
35. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89: 770-5.
36. Bersinger NA, Ødegård RA,. Serum levels of macrophage colony stimulating, vascular endothelial, and placenta growth factor in relation to later clinical onset of pre-eclampsia and a small-for-gestational age birth. Am J Reprod Immunol 2005; 54: 77-83.
37. Espinoza J, Romero R, Nien JK, Gomez R, Kusanovic JP, Gonçalves LF, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol 2007; 196: 326.e1-13.
38. Stepan H, Unversucht A, Wessel N, Faber R,. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007; 49: 818-24.
39. Wang Y, Tasevski V, Wallace EM, Gallery ED, Morris JM,. Reduced maternal serum concentrations of angiopoietin-2 in the first trimester precede intrauterine growth restriction associated with placental insufficiency. BJOG 2007; 114: 1427-31.
40. Diab AE, El-Behery MM, Ebrahiem MA, Shehata AE,. Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry. Int J Gynaecol Obstet 2008; 102: 146-51.
41. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008; 21: 279-87.
42. Poon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH,. Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn 2008; 28: 1110-5.
43. Åsvold BO, Vatten LJ, Romundstad PR, Jenum PA, Karumanchi SA, Eskild A,. Angiogenic factors in maternal circulation and the risk of severe fetal growth restriction. Am J Epidemiol 2011; 173: 630-9.
44. Vandenberghe G, Mensink I, Twisk JW, Blankenstein MA, Heijboer AC, van Vugt JM,. First trimester screening for intra-uterine growth restriction and early-onset pre-eclampsia. Prenat Diagn 2011; 31: 955-61.
45. Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, et al. Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction?. Am J Obstet Gynecol 2012; 206: 163.e1-7.
46. Boucoiran I, Thissier-Levy S, Wu Y, Wei SQ, Zhong-Cheng L, Delvin E, et al. Risk for preeclampsia and intrauterine growth restriction: effective value of PlGF, Sflt-1 and Inhibin Ain singleton and multiple pregnancies. Am J Obstet Gynecol 2012; 206 (Suppl): S336-7.
47. Murakami S, Matsubara N, Saitoh M, Miyakaw S, Shoji M, Kubo T,. The relation between plasma homocysteine concentration and methylenetetrahydrofolate reductase gene polymorphism in pregnant women. J Obstet Gynaecol Res 2001; 27: 349-52.
48. D'Anna R, Baviera G, Corrado F, Ientile R, Granese D, Stella NC,. Plasma homocysteine in early and late pregnancies complicated with preeclampsia and isolated intrauterine growth restriction. Acta Obstet Gynecol Scand 2004; 83: 155-8.
49. Onalan R, Onalan G, Gunenc Z, Karabulut E,. Combining 2nd-trimester maternal serum homocysteine levels and uterine artery Doppler for prediction of preeclampsia and isolated intrauterine growth restriction. Gynecol Obstet Invest 2006; 61: 142-8.
50. Dodds L, Fell DB, Dooley KC, Armson BA, Allen AC, Nassar BA, et al. Effect of homocysteine concentration in early pregnancy on gestational hypertensive disorders and other pregnancy outcomes. Clin Chem 2008; 54: 326-34.
51. Bergen NE, Jaddoe VW, Timmermans S, Hofman A, Lindemans J, Russcher H, et al. Homocysteine and folate concentrations in early pregnancy and the risk of adverse pregnancyoutcomes: the Generation R Study. BJOG 2012; 119: 739-51.
52. Franco-Sena AB, Goldani MZ, Tavares do Carmo MG, Velásquez- Melendez G, Kac G,. Low leptin concentration in the first gestational trimester is associated with being born small for gestational age: prospective study in Rio de Janeiro, Brazil. Neonatology. 2010; 97: 291-8.
53. Speer PD, Powers RW, Frank MP, Harger G, Markovic N, Roberts JM,. Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants. Am J Obstet Gynecol 2008; 198: 112.e1-7.
54. Krauss T, Emons G, Kuhn W, Augustin HG,. Predictive value of routine circulating soluble endothelial cell adhesion molecule measurements during pregnancy. Clin Chem 2002; 48: 1418-25.
55. Longini M, Perrone S, Kenanidis A, Vezzosi P, Marzocchi B, Petraglia F, et al. Isoprostanes in amniotic fluid: a predictive marker for fetal growth restriction in pregnancy. Free Radic Biol Med 2005; 38: 1537-41.
56. Stein TP, Scholl TO, Schluter MD, Leskiw MJ, Chen X, Spur BW, et al. Oxidative stress early in pregnancy and pregnancy outcome. Free Rad Res 2008; 42: 841-8.
57. Potdar N, Singh R, Mistry V, Evans MD, Farmer PB, Konje JC, et al. First-trimester increase in oxidative stress and risk of small-for-gestational- age fetus. BJOG 2009; 116: 637-42.
58. Wang Z, Xiong G, Zhu Y,. The predictive value of plasma fibronectin concentration on fetal growth retardation at earlier stage of the third trimester. J Tongji Med Univ 2001; 21: 253-5.
59. Borna S, Abdollahi A, Mirzaei F,. Predictive value of mid-trimester amniotic fluid high-sensitive C-reactive protein, ferritin, and lactate dehydrogenase for fetal growth restriction. Indian J Pathol Microbiol 2009; 52: 498-500.
60. Cetin I, Cozzi V, Papageorghiou AT, Maina V, Montanelli A, Garlanda C, et al. First trimester PTX3 levels in women who subsequently develop preeclampsia and fetal growth restriction. Acta Obstet Gynecol Scand 2009; 88: 846-9.
61. Georgiou HM, Thio YS, Russell C, Permezel M, Heng YJ, Lee S, et al. Association between maternal serum cytokine profiles at 7-10 weeks' gestation and birthweight in small for gestational age infants. Am J Obstet Gynecol 2011; 204: 415.e1-12.
62. Ernst GD, de Jonge LL, Hofman A, Lindemans J, Russcher H, Steegers EA, et al. C-reactive protein levels in early pregnancy, fetal growth patterns, and the risk for neonatal complications: the Generation R Study. Am J Obstet Gynecol 2011; 205: 132e1-12.
63. Bewley S, Chard T, Grudzinskas G, Cooper D, Campbell S,. Early prediction of uteroplacental complications of pregnancy using Doppler ultrasound, placental function tests and combination testing. Ultrasound Obstet Gynecol 1992; 2: 333-7.
64. Murisier-Petetin G, Gremlich S, Damnon F, Reymondin D, Hohlfeld P, Gerber S,. Amniotic fluid insulin-like growth factor binding protein 3 concentration as early indicator of fetal growth restriction. Eur J Obstet Gynecol Reprod Biol 2009; 144: 15-20.
65. Cowans NJ, Spencer K,. First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn 2007; 27: 264-71.
66. Pihl K, Larsen T, Krebs L, Christiansen M,. First trimester maternal serum PAPP-A, beta-hCG and ADAM12 in prediction of small-for-gestational-age fetuses. Prenat Diagn 2008; 28: 1131-5.
67. Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH,. First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet Gynecol 2008; 112: 1082-90.
68. Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007; 197: 35.e1-7.
69. Than NG, Romero R, Meiri H, Erez O, Xu Y, Tarquini F, et al. PP13, maternal ABO blood groups and the risk assessment of pregnancy complications. PLoS ONE 2011; 6: e21564.
70. Meints L, Cahill A, Huster K, Odibo L, McVean D, Odibo A,. PP13, PAPP-A, first-trimester uterine-artery Doppler measurements, and maternal characteristics in the prediction of small for gestational age fetuses. Am J Obstet Gynecol 2012; 206 (Suppl): S167.
71. Schneuer FJ, Nassar N, Khambalia AZ, Tasevski V, Ashton AW, Morris JM, et al. First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: In-house study and systematic review. Placenta 2012; 33: 735-40.
72. Ong CY, Liao AW, Munim S, Spencer K, Nicolaides KH,. First-trimester maternal serum activin A in pre-eclampsia and fetal growth restriction. J Matern Fetal Neonatal Med 2004; 15: 176-80.
73. Sifakis S, Akolekar R, Kappou D, Mantas N, Nicolaides KH,. Maternal serum placental growth hormone at 11-13 weeks' gestation in pregnancies delivering small for gestational age neonates. J Matern Fetal Neonatal Med 2012; 25: 1796-9.
74. Westergaard JG, Teisner B, Hau J, Grudzinskas JG,. Placental protein measurements in complicated pregnancies I. Intrauterine growth retardation. Br J Obstet Gynaecol 1984; 91: 1216-23.
75. Pihl K, Larsen T, Laursen I, Krebs L, Christiansen M,. First trimester maternal serum pregnancy-specific beta-1-glycoprotein (SP1) as a marker of adverse pregnancy outcome. Prenat Diagn 2009; 29: 1256-61.
76. Van Eerden P, Wu XX, Chazotte C, Rand JH,. Annexin A5 levels in midtrimester amniotic fluid: association with intrauterine growth restriction. Am J Obstet Gynecol 2006; 194: 1371-6.
77. Clark DE, Salvig JD, Smith SK, Charnock-Jones DS,. Hepatocyte growth factor levels during normal and intra-uterine growth-restricted pregnancies. Placenta 1998; 19: 671-3.
78. Tjoa ML, Mulders MA, van Vugt JM, Blankenstein MA, Oudejans CB, van Wijk IJ,. Plasma hepatocyte growth factor as a marker for small-for-gestational age fetuses. Eur J Obstet Gynecol Reprod Biol 2003; 110: 20-5.
79. Baweja S, Kent A, Masterson R, Roberts S, McMahon LP,. Prediction of pre-eclampsia in early pregnancy by estimating the spot urinary albumin:creatinine ratio using high-performance liquid chromatography. BJOG 2011; 118: 1126-32.
80. Bodnar LM, Catov JM, Zmuda JM, Cooper ME, Parrott MS, Roberts JM, et al. Maternal serum 25-hydroxyvitamin D concentrations are associated with small-for-gestational age births in white women. J Nutr 2010; 140: 999-1006.
81. Ertl R, Yu CK, Samaha R, Akolekar R, Nicolaides KH,. Maternal serum vitamin D at 11-13 weeks in pregnancies delivering small for gestational age neonates. Fetal Diagn Ther 2012; 31: 103-8.
82. Karagiannis G, Ashoor G, Maiz N, Jawdat F, Nicolaides KH,. Maternal thyroid function at eleven to thirteen weeks of gestation and subsequent delivery of small for gestational age neonates. Thyroid 2011; 21: 1127-31.
83. Horgan RP, Broadhurst DI, Walsh SK, Dunn WB, Brown M, Roberts CT, et al. Metabolic profiling uncovers a phenotypic signature of small for gestational age in early pregnancy. J Proteome Res 2011; 10: 3660-73.
84. Heazell AE, Bernatavicius G, Warrander L, Brown MC, Dunn WB,. A metabolomic approach identifies differences in maternal serum in third trimester pregnancies that end in poor perinatal outcome. Reprod Sci 2012; 19: 863-75.
85. Conde-Agudelo A, Papageorghiou AT, Kennedy SH, Villar J,. Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis. BJOG 2011; 118: 1042-54.
86. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, Van der Meulen JH, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999; 282: 1061-6. Erratum in JAMA 2000;283:1963.
87. Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH,. Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks. Fetal Diagn Ther 2011; 29: 148-54.
88. Papastefanou I, Souka AP, Pilalis A, Eleftheriades M, Michalitsi V, Kassanos D,. First trimester prediction of small- and large-for-gestation neonates by an integrated model incorporating ultrasound parameters, biochemical indices and maternal characteristics. Acta Obstet Gynecol Scand 2012; 91: 104-11.